Cullinan Therapeutics Inc

For the period ended Dec 31, 2024. Filed Feb 27, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 27, 2025

CGEM$11.23-4.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Income (Loss)

(in thousands, except per share amounts)

	2024	2023
Operating expenses:
Research and development	$142,903	$148,156
General and administrative	54,016	42,493
Total operating expenses	196,919	190,649
Impairment of long-lived assets	—	(440)
Loss from operations	(196,919)	(191,089)
Other income (expense):
Interest income	29,660	21,627
Other income (expense), net	(199)	239
Net loss before income taxes	(167,458)	(169,223)
Income tax expense (benefit)	117	(14,122)
Net loss	(167,575)	(155,101)
Net loss attributable to noncontrolling interests	(192)	(1,939)
Net loss attributable to Cullinan	$(167,383)	$(153,162)
Comprehensive income (loss):
Net loss	$(167,575)	$(155,101)
Unrealized gain (loss) on investments	(4)	2,472
Comprehensive loss	$(167,579)	$(152,629)
Comprehensive loss attributable to noncontrolling interests	(192)	(1,939)
Comprehensive loss attributable to Cullinan	$(167,387)	$(150,690)
Basic and diluted net loss per share attributable to Cullinan:
Common stock	$(2.78)	$(3.21)
Preferred stock	$(27.78)	$(32.12)
Weighted-average shares used in computing basic and diluted net loss per share attributable to Cullinan:
Common stock	53,771	41,550
Preferred stock	648	614

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.